Dose May Matter: CYP2C19 Genotype and PPI Response in Pediatric Eosinophilic Esophagitis.

Authors

Paroma Bose, Chizoba N Umeweni, Anthony Perkins, Elizabeth T Jensen, Evan S Dellon, Amanda B Muir, Sandeep K Gupta

Published in

The American journal of gastroenterology. Jul 10, 2026. Epub Jul 10, 2026.

Abstract

Little is known about the effect of proton pump inhibitor (PPI) metabolism, based on CYP2C19 genotype, on treatment response in pediatric eosinophilic esophagitis (EoE).
We conducted a cohort study of pediatric subjects with active histologic EoE treated with PPI therapy. Whole blood samples were tested for CYP2C19 genotype.
Among subjects prescribed high PPI dose > 1mg/kg/day, intermediate/slow PPI metabolizers were significantly more likely to have histologic response to PPI therapy compared to normal and rapid PPI metabolizers. No ultra-rapid metabolizers responded to PPI therapy.
Knowing CYP2C19 genotype may optimize PPI dose for the treatment of EoE in individual patients.

PMID:
42439590
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.